Patent applications published 14 April 2010
Patent applications taken from the weekly European Patents Bulletin
- Antibody formulations
GlaxoSmithKline 2173163*
- Inhibitors of polysialic acid de-N-acetylase and methods for using the same
Children’s Hospital and Research Centre at Oakland 2173166*
- Treatment of neuropathic pain
Nuon Therapeutics 2173167*
- Vesicles for active macromolecule delivery
BioCure 2173168*
- Nasal and ophthalmic delivery of aqueous corticosteroids
CyDex Pharmaceuticals 2173169*
- Fused heterocycles
Sepracor 2173170*
- Orally disintegrating tablet compsns of lamotrigine
Eurand 2173172*
- Substituted 6-anilinopurine derivatives of cytokin oxidase/dehydroganase and preparations containing these derivatives
Univerzita palackenho V Olomouci; Freie Universität Berlin 2173173*
- Farnesoid X-receptor agonists
GlaxoSmithKline 2173174*
- Organosilane-nonionic-water stable quaternary ammonium compsns and methods
Higgins, Thomas; Shlisky, Theodore 2173175*
- Methods of and formulations for reducing and inhibiting the growth of the concentrations of microbes in water-based fluids and systems using with them
Dow Global Technologies 2173176*
- Metronidazole containing extended release floating pharmaceutical compsn
Richter Gideon Nyrt 2173320*
- Tabletable formulations of lipophilic health ingredients
DSM IP Assets 2173321*
- A pharmaceutical compsn comprising polyaphron dispersion
Drug Delivery Solutions 2173322*
- Stimulating gel
LRC Products 2173323*
- Hyaluronic acid injectable gel for treating joint degeneration
Anteis 2173324*
- Peptide slow-release formulations
Camurus 2173325*
- Dermatological compsn containing calcitrol lipidic vesicles, method for preparing same and use thereof
Galderma 2173326*
- Technology for the preparation of microparticles
Nexbio 2173327*
- Solid varsartan compsn
Generics (UK) 2173328*
- Tolterodine bead
Synthon 2173329*
- Treatment of macular degeneration
Summit (Cambridge) 2173331*
- New pharmaceutical formulation comprising cannabidiol and tetrahydro-cannabidivarin
GW Pharma 2173332*
- Combinations of antifolate agent and methoxyamine in the treatment of cancer
Tracon Pharmaceuticals 2173333*
- A method of treating amblyopia
Hermo Pharma 2173334*
- Beta adrenergic receptor ligand derivatives for modulating apoptosis
Sanofi-Aventis 2173335*
- New use of known pharmacologically active chemical compounds
Entress 2173336*
- Phosphoplatins and their use in the treatment of cancers resistant to cisplatin and carboplatin
Ohio University 2173337*
- Combination anti-cancer therapy
OSI Pharmaceuticals 2173338*
- Campsiandra angustifolia extract and methods of extracting and using such
Selvamedica 2173339*
- Methods of enhancing cognitive function using non-peptidic compounds
Acumen Pharmaceuticals 2173340*
- Combinations of SAP depleting agents and anti-SAP antibodies
Pentraxin Therapeutics 2173341*
- Antivirals
ETH Zurich 2173342*
- Use of pimavanserin in the treatment of Parkinsons and symptoms thereof
Acadia Pharmaceuticals 2173343*
- Treatment or prophylaxis of neurological or neuropsychiatric disorders via ocular administration
Clarence Pty 2173344*
- A method for decreasing symptoms of alcohol consumption
Alcobra 2173345*
- Use of compounds for preparing anti-tuberculosis agents
Summit Corp 2173346*
- Pharmaceutical compsn, substrate comprising a pharmaceutical compsn, and use of a pharmaceutical compsn
Biomet Deutschland 2173347*
- Potentiation of cancer chemotherapy
Eli Lilly 2173348*
- Antitumour combinations containing a VEGF agent and irinotecan
Aventis Pharma 2173349*
- Stereoselective process for preparing purine dioxolane nucleoside derivatives
RFS Pharma 2173350*
- Compounds and methods for treatment of sickle cell disease or complications associated therewith
GlycoMimetics 2173351*
- Inhibitors of AKT/PKB with antitumour activity
University of South Florida 2173352*
- Transplants
Hibernation Therapeutics 2173353*
- Quinoxaline derivatives as P13 kinase inhibitors
GlaxoSmithKline 2173354*
- Pirenzepine and derivatives thereof as anti-amyloid agents
AC Immune 2173355*
- Use of 25-hydroxy vitamin D3 to increase muscle mass in mammals
DSM IP 2173356*
- Metal complexes incorporated within biodegradable nanoparticles and their use
The University of Akron 2173357*
- Double strand compsns comprising differentially modified strands for use in gene modulation
Isis Pharmaceuticals 2173358*
- Heparin conjugates and methods
Mediplex 2173359*
- Heparosan-based biomaterials and coatings and methods of production and use thereof
The Board of Regents for the University of Oklahoma 2173360*
- Treating or preventing rotavirus infection
Fonterra Co-operative Group 2173364*
- Medicament for treating Parkinson’s disease
Assistance Publique - Hôpitaux de Paris 2173365*
- Medicament for treating Parkinson’s disease
Assistance Publique - Hôpitaux de Paris 2173366*
- Use of a chemotherapeutic agent in the preparation of a medicament for treating or ameliorating an adverse side effect associated with oncolytic viral therapy
Genelux 2173369*
- Novel method for screening brain-active compounds
DSM IP 2173369*
- Oligopeptide tyrosinase inhibitors and uses thereof
The Board of Trustees of the Leland Stanford University 2173370*
- Peptides derived from plasminogen activator inhibitor-1 and uses thereof
Thrombotech 2173371*
- Novel peptides and protein and uses thereof
Agency for Science, Technology and Research 2173372*
- Soluble HER2 and HER3 splice variant proteins, splice-switching oligonucleotides, and their use in the treatment of disease
AVI BioPharma; The University of North Carolina at Chapel Hill 2173373*
- Compsns and methods for generating an immune response in a subject
Stichting Katholieke Universiteit 2173374*
- Methods and substances for the treatment of Alzheimer’s
Paul-Ehrlich-Institut für Sera und Impfstoffe 2173375*
- Multimeric multiepitope influenza vaccines
Biondvax Pharmaceuticals 2173376*
- Antibody-endostatin fusion protein and its variants
University of Miami 2173377*
- Complexes of IL-15 and IL-15R alpha and uses thereof
Marine Polymer Technologies; The United States of America, as represented by the Secretary, Department of Health and Human Services 2173378*
- Compsns and methods for treating and diagnosing cancer
Oncomed Pharmaceuticals 2173379*
- Methods and compsns for pulmonary administration of a TNFa inhibitor
Abbott Biotechnology 2173380*
- FC receptor-binding polypeptides with modified effector functions
Novimmune SA 2173381*
- Wound repair compsn and method
Queensland University of Technology 2173382*
- Hydrolysable polymeric FMOC-linker
Baxter International; Baxter Healthcare 2173383*
- Caspase inhibitors for treating pathologies resulting from ischaemia
Chiesi Farmaceutici; Institut National de la Santé et de la Recherche Médicale (INSERM) 2173384*
- Chlorotoxins as drug carriers
Transmolecular 2173385*
- Use of VHH antibodies for the preparation of peptide vectors for delivering a substance of interest and their applications
Institut Pasteur; Centre National de la Recherche Scientifique 2173386*